{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,8]],"date-time":"2026-03-08T22:34:55Z","timestamp":1773009295939,"version":"3.50.1"},"reference-count":53,"publisher":"Oxford University Press (OUP)","issue":"9","license":[{"start":{"date-parts":[[2020,6,17]],"date-time":"2020-06-17T00:00:00Z","timestamp":1592352000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"National Health Institute Carlos III","award":["CPII15\/00014"],"award-info":[{"award-number":["CPII15\/00014"]}]},{"name":"Catalan Government and the European Social Fund"},{"name":"ISCIII RETIC","award":["RD16\/0025\/0041"],"award-info":[{"award-number":["RD16\/0025\/0041"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,9,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Virological failure (VF) to boosted PIs with a high genetic barrier is not usually linked to the development of resistance-associated mutations in the protease gene.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>From a cohort of 520 HIV-infected subjects treated with lopinavir\/ritonavir or darunavir\/ritonavir monotherapy, we retrospectively identified nine patients with VF. We sequenced the HIV-1 Gag-protease region and generated clonal virus from plasma samples. We characterized phenotypically clonal variants in terms of replicative capacity and susceptibility to PIs. Also, we used VESPA to identify signature mutations and 3D molecular modelling information to detect conformational changes in the Gag region.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>All subjects analysed harboured Gag-associated polymorphisms in the absence of resistance mutations in the protease gene. Most Gag changes occurred outside Gag cleavage sites. VESPA analyses identified K95R and R286K (P\u2009&amp;lt;\u20090.01) as signature mutations in Gag present at VF. In one out of four patients with clonal analysis available, we identified clonal variants with high replicative capacity and 8- to 13-fold reduction in darunavir susceptibility. These clonal variants harboured K95R, R286K and additional mutations in Gag. Low susceptibility to darunavir was dependent on the Gag sequence context. All other clonal variants analysed preserved drug susceptibility and virus replicative capacity.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Gag mutations may reduce darunavir susceptibility in the absence of protease mutations while preserving viral fitness. This effect is Gag-sequence context dependent and may occur during boosted PI failure.<\/jats:p><\/jats:sec>","DOI":"10.1093\/jac\/dkaa228","type":"journal-article","created":{"date-parts":[[2020,5,19]],"date-time":"2020-05-19T11:29:45Z","timestamp":1589887785000},"page":"2535-2546","source":"Crossref","is-referenced-by-count":9,"title":["HIV-1 Gag mutations alone are sufficient to reduce darunavir susceptibility during virological failure to boosted PI therapy"],"prefix":"10.1093","volume":"75","author":[{"given":"Oscar","family":"Blanch-Lombarte","sequence":"first","affiliation":[{"name":"IrsiCaixa AIDS Research Institute, Badalona, Spain"},{"name":"Germans Trias i Pujol Research Institute (IGTP), Badalona, Spain and Universitat Aut\u00f2noma de Barcelona, Cerdanyola del Vall\u00e8s, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0886-7114","authenticated-orcid":false,"given":"Jos\u00e9 R","family":"Santos","sequence":"additional","affiliation":[{"name":"Lluita contra la SIDA Foundation, Hospital Universitari Germans Trias i Pujol, Badalona, Spain"},{"name":"Infectious Diseases Department, Hospital Universitari Germans Trias i Pujol, Badalona, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ruth","family":"Pe\u00f1a","sequence":"additional","affiliation":[{"name":"IrsiCaixa AIDS Research Institute, Badalona, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Esther","family":"Jim\u00e9nez-Moyano","sequence":"additional","affiliation":[{"name":"IrsiCaixa AIDS Research Institute, Badalona, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bonaventura","family":"Clotet","sequence":"additional","affiliation":[{"name":"IrsiCaixa AIDS Research Institute, Badalona, Spain"},{"name":"Faculty of Medicine, University of Vic - Central University of Catalonia (UVic-UCC), Vic, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roger","family":"Paredes","sequence":"additional","affiliation":[{"name":"IrsiCaixa AIDS Research Institute, Badalona, Spain"},{"name":"Faculty of Medicine, University of Vic - Central University of Catalonia (UVic-UCC), Vic, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julia G","family":"Prado","sequence":"additional","affiliation":[{"name":"IrsiCaixa AIDS Research Institute, Badalona, Spain"},{"name":"Germans Trias i Pujol Research Institute (IGTP), Badalona, Spain and Universitat Aut\u00f2noma de Barcelona, Cerdanyola del Vall\u00e8s, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2020,6,17]]},"reference":[{"key":"2020082404582705300_dkaa228-B1","year":"2020"},{"key":"2020082404582705300_dkaa228-B2","year":"2019"},{"key":"2020082404582705300_dkaa228-B3","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1001\/jama.2018.8431","article-title":"Antiretroviral drugs for treatment and prevention of HIV infection in adults: 2018 recommendations of the international antiviral society-USA panel","volume":"320","author":"Saag","year":"2018","journal-title":"JAMA"},{"key":"2020082404582705300_dkaa228-B4","year":"2019"},{"key":"2020082404582705300_dkaa228-B5","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1111\/j.1468-1293.2012.01060.x","article-title":"Final 192-week efficacy and safety of once-daily darunavir\/ritonavir compared with lopinavir\/ritonavir in HIV-1-infected treatment-na\u00efve patients in the ARTEMIS trial","volume":"14","author":"Orkin","year":"2013","journal-title":"HIV Med"},{"key":"2020082404582705300_dkaa228-B6","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1186\/s12916-018-1046-2","article-title":"Switching to dual\/monotherapy determines an increase in CD8+ in HIV-infected individuals: an observational cohort study","volume":"16","author":"Mussini","year":"2018","journal-title":"BMC Med"},{"key":"2020082404582705300_dkaa228-B7","doi-asserted-by":"crossref","first-page":"e23","DOI":"10.1016\/S2352-3018(17)30179-0","article-title":"Efficacy and safety of switching from boosted protease inhibitors plus emtricitabine and tenofovir disoproxil fumarate regimens to single-tablet darunavir, cobicistat, emtricitabine, and tenofovir alafenamide at 48 weeks in adults with virologically suppressed HIV-1 (EMERALD): a phase 3, randomised, non-inferiority trial","volume":"5","author":"Orkin","year":"2018","journal-title":"Lancet HIV"},{"key":"2020082404582705300_dkaa228-B8","doi-asserted-by":"crossref","first-page":"2222","DOI":"10.1016\/S0140-6736(14)60084-2","article-title":"Once-daily dolutegravir versus darunavir plus ritonavir in antiretroviral-naive adults with HIV-1 infection (FLAMINGO): 48 week results from the randomised open-label phase 3b study","volume":"383","author":"Clotet","year":"2014","journal-title":"Lancet"},{"key":"2020082404582705300_dkaa228-B9","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1093\/jac\/dku509","article-title":"Monotherapy with boosted PIs as an ART simplification strategy in clinical practice","volume":"70","author":"Santos","year":"2014","journal-title":"J Antimicrob Chemother"},{"key":"2020082404582705300_dkaa228-B10","doi-asserted-by":"crossref","first-page":"2509","DOI":"10.3390\/v2112509","article-title":"Molecular basis for drug resistance in HIV-1 protease","volume":"2","author":"Ali","year":"2010","journal-title":"Viruses"},{"key":"2020082404582705300_dkaa228-B11","doi-asserted-by":"crossref","first-page":"11956","DOI":"10.1021\/ja504096m","article-title":"Drug resistance conferred by mutations outside the active site through alterations in the dynamic and structural ensemble of HIV-1 protease","volume":"136","author":"Ragland","year":"2014","journal-title":"J Am Chem Soc"},{"key":"2020082404582705300_dkaa228-B12","doi-asserted-by":"crossref","first-page":"5368","DOI":"10.1128\/JVI.02531-09","article-title":"Evaluating the substrate-envelope hypothesis: structural analysis of novel HIV-1 protease inhibitors designed to be robust against drug resistance","volume":"84","author":"Nalam","year":"2010","journal-title":"J Virol"},{"key":"2020082404582705300_dkaa228-B13","doi-asserted-by":"crossref","first-page":"e1000345","DOI":"10.1371\/journal.ppat.1000345","article-title":"Gag mutations strongly contribute to HIV-1 resistance to protease inhibitors in highly drug-experienced patients besides compensating for fitness loss","volume":"5","author":"Dam","year":"2009","journal-title":"PLoS Pathog"},{"key":"2020082404582705300_dkaa228-B14","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1128\/JVI.75.2.589-594.2001","article-title":"Human immunodeficiency virus type 1 protease cleavage site mutations associated with protease inhibitor cross-resistance selected by indinavir, ritonavir, and\/or saquinavir","volume":"75","author":"C\u00f4t\u00e9","year":"2001","journal-title":"J Virol"},{"key":"2020082404582705300_dkaa228-B15","doi-asserted-by":"crossref","first-page":"3243","DOI":"10.3390\/molecules24183243","article-title":"Reviewing HIV-1 Gag mutations in protease inhibitors resistance: insights for possible novel Gag inhibitor designs","volume":"24","author":"Su","year":"2019","journal-title":"Molecules"},{"key":"2020082404582705300_dkaa228-B16","doi-asserted-by":"crossref","first-page":"5952","DOI":"10.1074\/jbc.M108005200","article-title":"Amino acid substitutions in Gag protein at non-cleavage sites are indispensable for the development of a high multitude of HIV-1 resistance against protease inhibitors","volume":"277","author":"Gatanaga","year":"2002","journal-title":"J Biol Chem"},{"key":"2020082404582705300_dkaa228-B17","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1128\/AAC.48.2.444-452.2004","article-title":"Gag non-cleavage site mutations contribute to full recovery of viral fitness in protease inhibitor-resistant human immunodeficiency virus type 1","volume":"48","author":"Myint","year":"2004","journal-title":"Antimicrob Agents Chemother"},{"key":"2020082404582705300_dkaa228-B18","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1111\/j.1468-1293.2009.00752.x","article-title":"Long-term (96-week) follow-up of antiretroviral-na\u00efve HIV-infected patients treated with first-line lopinavir\/ritonavir monotherapy in the MONARK trial","volume":"11","author":"Ghosn","year":"2010","journal-title":"HIV Med"},{"key":"2020082404582705300_dkaa228-B19","doi-asserted-by":"crossref","first-page":"e417","DOI":"10.1016\/S2352-3018(15)00176-9","article-title":"Protease inhibitor monotherapy for long-term management of HIV infection: a randomised, controlled open-label, non-inferiority trial","volume":"2","author":"Paton","year":"2015","journal-title":"Lancet HIV"},{"key":"2020082404582705300_dkaa228-B20","doi-asserted-by":"crossref","first-page":"e36","DOI":"10.1371\/journal.pmed.0040036","article-title":"A novel substrate-based HIV-1 protease inhibitor drug resistance mechanism","volume":"4","author":"Nijhuis","year":"2007","journal-title":"PLoS Med"},{"key":"2020082404582705300_dkaa228-B21","doi-asserted-by":"crossref","first-page":"3848","DOI":"10.1172\/JCI67399","article-title":"Multi-step inhibition explains HIV-1 protease inhibitor pharmacodynamics and resistance","volume":"123","author":"Rabi","year":"2013","journal-title":"J Clin Invest"},{"key":"2020082404582705300_dkaa228-B22","doi-asserted-by":"crossref","first-page":"3340","DOI":"10.1093\/jac\/dku296","article-title":"Phenotypic characterization of virological failure following lopinavir\/ritonavir monotherapy using full-length gag-protease genes","volume":"69","author":"Sutherland","year":"2014","journal-title":"J Antimicrob Chemother"},{"key":"2020082404582705300_dkaa228-B23","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1099\/vir.0.055624-0","article-title":"Contribution of Gag and protease to variation in susceptibility to protease inhibitors between different strains of subtype B human immunodeficiency virus type 1","volume":"95","author":"Sutherland","year":"2014","journal-title":"J Gen Virol"},{"key":"2020082404582705300_dkaa228-B24","doi-asserted-by":"crossref","first-page":"e0137834","DOI":"10.1371\/journal.pone.0137834","article-title":"Evidence for reduced drug susceptibility without emergence of major protease mutations following protease inhibitor monotherapy failure in the SARA trial","volume":"10","author":"Sutherland","year":"2015","journal-title":"PLoS One"},{"key":"2020082404582705300_dkaa228-B25","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1128\/AAC.01228-10","article-title":"Three residues in HIV-1 matrix contribute to protease inhibitor susceptibility and replication capacity","volume":"55","author":"Parry","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"2020082404582705300_dkaa228-B26","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1186\/1742-4690-9-63","article-title":"Human immunodeficiency virus gag and protease: partners in resistance","volume":"9","author":"Fun","year":"2012","journal-title":"Retrovirology"},{"key":"2020082404582705300_dkaa228-B27","doi-asserted-by":"crossref","first-page":"3717","DOI":"10.1038\/s41598-017-03260-4","article-title":"Gag-protease coevolution analyses define novel structural surfaces in the HIV-1 matrix and capsid involved in resistance to protease inhibitors","volume":"7","author":"Codo\u00f1er","year":"2017","journal-title":"Sci Rep"},{"key":"2020082404582705300_dkaa228-B28","doi-asserted-by":"crossref","first-page":"e1004249","DOI":"10.1371\/journal.pcbi.1004249","article-title":"Deep sequencing of protease inhibitor resistant HIV patient isolates reveals patterns of correlated mutations in Gag and protease","volume":"11","author":"Flynn","year":"2015","journal-title":"PLoS Comput Biol"},{"key":"2020082404582705300_dkaa228-B29","doi-asserted-by":"crossref","first-page":"1679","DOI":"10.1093\/jac\/dkz043","article-title":"HIV-1 protease, Gag and gp41 baseline substitutions associated with virological response to a PI-based regimen","volume":"74","author":"Perrier","year":"2019","journal-title":"J Antimicrob Chemother"},{"key":"2020082404582705300_dkaa228-B30","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1089\/aid.2015.0138","article-title":"Gag-protease sequence evolution following protease inhibitor monotherapy treatment failure in HIV-1 viruses circulating in East Africa","volume":"31","author":"Sutherland","year":"2015","journal-title":"AIDS Res Hum Retroviruses"},{"key":"2020082404582705300_dkaa228-B31","doi-asserted-by":"crossref","first-page":"e24798","DOI":"10.1371\/journal.pone.0024798","article-title":"Polymorphism in gag gene cleavage sites of HIV-1 non-B subtype and virological outcome of a first-line lopinavir\/ritonavir single drug regimen","volume":"6","author":"Ghosn","year":"2011","journal-title":"PLoS One"},{"key":"2020082404582705300_dkaa228-B32","doi-asserted-by":"crossref","first-page":"11279","DOI":"10.1128\/JVI.01144-10","article-title":"HLA-Cw*03-restricted CD8+ T-cell responses targeting the HIV-1 Gag major homology region drive virus immune escape and fitness constraints compensated for by intracodon variation","volume":"84","author":"Honeyborne","year":"2010","journal-title":"J Virol"},{"key":"2020082404582705300_dkaa228-B33","first-page":"493","article-title":"A simple method of estimating fifty percent endpoints","volume":"27","author":"Reed","year":"1938","journal-title":"Am J Hyg"},{"key":"2020082404582705300_dkaa228-B34"},{"key":"2020082404582705300_dkaa228-B35"},{"key":"2020082404582705300_dkaa228-B36","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1128\/JVI.01882-08","article-title":"Functional consequences of human immunodeficiency virus escape from an HLA-B*13-restricted CD8+ T-cell epitope in p1 Gag protein","volume":"83","author":"Prado","year":"2009","journal-title":"J Virol"},{"key":"2020082404582705300_dkaa228-B37","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.1128\/JVI.78.4.1718-1729.2004","article-title":"Novel single-cell-level phenotypic assay for residual drug susceptibility and reduced replication capacity of drug-resistant human immunodeficiency virus type 1","volume":"78","author":"Zhang","year":"2004","journal-title":"J Virol"},{"key":"2020082404582705300_dkaa228-B38","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1093\/nar\/28.1.235","article-title":"The Protein Data Bank","volume":"28","author":"Berman","year":"2000","journal-title":"Nucleic Acids Res"},{"key":"2020082404582705300_dkaa228-B39","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1128\/JVI.02539-08","article-title":"Non-cleavage site Gag mutations in amprenavir-resistant human immunodeficiency virus type 1 (HIV-1) predispose HIV-1 to rapid acquisition of amprenavir resistance but delay development of resistance to other protease inhibitors","volume":"83","author":"Aoki","year":"2009","journal-title":"J Virol"},{"key":"2020082404582705300_dkaa228-B40","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1097\/00002030-200205030-00007","article-title":"Amprenavir-resistant HIV-1 exhibits lopinavir cross-resistance and reduced replication capacity","volume":"16","author":"Prado","year":"2002","journal-title":"AIDS"},{"key":"2020082404582705300_dkaa228-B41","doi-asserted-by":"crossref","first-page":"e94240","DOI":"10.1371\/journal.pone.0094240","article-title":"Impact of mutations in highly conserved amino acids of the HIV-1 Gag-p24 and Env-gp120 proteins on viral replication in different genetic backgrounds","volume":"9","author":"Liu","year":"2014","journal-title":"PLoS One"},{"key":"2020082404582705300_dkaa228-B42","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1097\/QAD.0b013e32833160fa","article-title":"High prevalence of bevirimat resistance mutations in protease inhibitor-resistant HIV isolates","volume":"24","author":"Verheyen","year":"2010","journal-title":"AIDS"},{"key":"2020082404582705300_dkaa228-B43","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/j.jinf.2006.06.012","article-title":"Association of Gag cleavage sites to protease mutations and to virological response in HIV-1 treated patients","volume":"54","author":"Malet","year":"2007","journal-title":"J Infect"},{"key":"2020082404582705300_dkaa228-B44","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1186\/s12977-014-0079-7","article-title":"HIV-1 Gag C-terminal amino acid substitutions emerging under selective pressure of protease inhibitors in patient populations infected with different HIV-1 subtypes","volume":"11","author":"Li","year":"2014","journal-title":"Retrovirology"},{"key":"2020082404582705300_dkaa228-B45","doi-asserted-by":"crossref","first-page":"11027","DOI":"10.1128\/JVI.00628-09","article-title":"Human immunodeficiency virus type 1 protease-correlated cleavage site mutations enhance inhibitor resistance","volume":"83","author":"Kolli","year":"2009","journal-title":"J Virol"},{"key":"2020082404582705300_dkaa228-B46","doi-asserted-by":"crossref","first-page":"9094","DOI":"10.1128\/JVI.02356-08","article-title":"Gag determinants of fitness and drug susceptibility in protease inhibitor-resistant human immunodeficiency virus type 1","volume":"83","author":"Parry","year":"2009","journal-title":"J Virol"},{"key":"2020082404582705300_dkaa228-B47","doi-asserted-by":"crossref","first-page":"3744","DOI":"10.1128\/JVI.73.5.3744-3752.1999","article-title":"Replicative fitness of protease inhibitor-resistant mutants of human immunodeficiency virus type 1","volume":"73","author":"Martinez-Picado","year":"1999","journal-title":"J Virol"},{"key":"2020082404582705300_dkaa228-B48","doi-asserted-by":"crossref","first-page":"2019","DOI":"10.1093\/jac\/dkz151","article-title":"New mechanisms of resistance in virological failure to protease inhibitors: selection of non-described protease, Gag and Gp41 mutations","volume":"74","author":"Castain","year":"2019","journal-title":"J Antimicrob Chemother"},{"key":"2020082404582705300_dkaa228-B49","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1128\/JVI.71.2.1089-1096.1997","article-title":"Impaired fitness of human immunodeficiency virus type 1 variants with high-level resistance to protease inhibitors","volume":"71","author":"Croteau","year":"1997","journal-title":"J Virol"},{"key":"2020082404582705300_dkaa228-B50","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1371\/journal.ppat.1005990","article-title":"Mechanistic studies and modeling reveal the origin of differential inhibition of Gag polymorphic viruses by HIV-1 maturation inhibitors","volume":"12","author":"Lin","year":"2016","journal-title":"PLoS Pathog"},{"key":"2020082404582705300_dkaa228-B51","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1093\/cid\/ciy463","article-title":"Human immunodeficiency virus drug resistance: 2018 recommendations of the International Antiviral Society-USA Panel","volume":"68","author":"G\u00fcnthard","year":"2019","journal-title":"Clin Infect Dis"},{"key":"2020082404582705300_dkaa228-B52","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1093\/jac\/dkx042","article-title":"Prevalence of HIV-1 drug resistance in treated patients with viral load &gt;50 copies\/mL: a 2014 French nationwide study","volume":"72","author":"Assoumou","year":"2017","journal-title":"J Antimicrob Chemother"},{"key":"2020082404582705300_dkaa228-B53","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1093\/cid\/ciu019","article-title":"Performance of HIV-1 drug resistance testing at low-level viremia and its ability to predict future virologic outcomes and viral evolution in treatment-naive individuals","volume":"58","author":"Gonzalez-Serna","year":"2014","journal-title":"Clin Infect Dis"}],"container-title":["Journal of Antimicrobial Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jac\/article-pdf\/75\/9\/2535\/33665195\/dkaa228.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/jac\/article-pdf\/75\/9\/2535\/33665195\/dkaa228.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,24]],"date-time":"2022-10-24T06:18:09Z","timestamp":1666592289000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jac\/article\/75\/9\/2535\/5858390"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,17]]},"references-count":53,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2020,6,17]]},"published-print":{"date-parts":[[2020,9,1]]}},"URL":"https:\/\/doi.org\/10.1093\/jac\/dkaa228","relation":{},"ISSN":["0305-7453","1460-2091"],"issn-type":[{"value":"0305-7453","type":"print"},{"value":"1460-2091","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2020,9]]},"published":{"date-parts":[[2020,6,17]]}}}